title: The Development of Prophylactic and Therapeutic EBV Vaccines.
abstract: Over the last century, the development of effective vaccine approaches to treat a number of viral infections has provided the impetus for the continual development of vaccine platforms for other viral infections, including Epstein-Barr virus (EBV). The clinical manifestations associated with EBV infection occur either following primary infection, such as infectious mononucleosis, or following an extended period of latency, primarily the EBV-associated malignancies and potentially including a number of autoimmune disorders, such as multiple sclerosis. As a consequence, two independent vaccine approaches are under development to prevent or control EBV-associated diseases. The first approach, which has been widely successful against other viral infections, is aimed at inducing a viral neutralisation antibody response to prevent primary infection. The second approach focuses upon the induction of cell-mediated immunity to control latent infected cells in persistently infected individuals. Early clinical studies have offered some insight into the potential efficacy of both of these approaches.
authors.affiliation: QIMR Centre for Immunotherapy and Vaccine Development and Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4029, Australia.
authors.forename: Corey
authors.initials: C
authors.lastname: Smith
authors.affiliation: QIMR Centre for Immunotherapy and Vaccine Development and Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4029, Australia. rajiv.khanna@qimrberghofer.edu.au.|Tumour Immunology Laboratory, Department of Immunology, QIMR Berghofer Medical Research Institute, 300 Herston Rd, Brisbane, 4006, Australia. rajiv.khanna@qimrberghofer.edu.au.
authors.forename: Rajiv
authors.initials: R
authors.lastname: Khanna
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D020031:Epstein-Barr Virus Infections / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy / Q000821:virology; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000276:immunology*; D022283:Herpesvirus Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D006801:Humans; D014764:Viral Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
chemical_list: D022283:Herpesvirus Vaccines; D014764:Viral Proteins
keywords: Antigen processing; Epitope; T cells; Vaccine; Virus